Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Authors

Barry A Singer, Missouri Baptist Medical Center
Robert T Naismith, Washington University School of Medicine in St. Louis
et al.

Journal

Multiple Sclerosis Journal

Publication Date

12-1-2023

Volume

29

Issue

14

First Page

1795

Last Page

1807

Document Type

Open Access Publication

DOI

10.1177/13524585231205708

Rights and Permissions

Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2023 Dec;29(14):1795-1807. doi: 10.1177/13524585231205708. Epub 2023 Oct 31. © The Author(s), 2023. Creative Commons License (CC BY-NC 4.0) This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

Recommended Citation

Singer, Barry A; Naismith, Robert T; and et al., "Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study." Multiple Sclerosis Journal. 29, 14. 1795 - 1807. (2023).
https://digitalcommons.wustl.edu/oa_4/2716

Department

ICTS (Institute of Clinical and Translational Sciences)